SCHEMBL638027

SCHEMBL638027

C[C@@H]1Cc2cc(O)cc(O)c2C(=O)O1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 7/20 0.64
MAOB P27338 5/20 0.64
LMNA P02545 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
ESR2 Q92731 3/20 0.60
ALDH1A1 P00352 2/20 0.60
HSP90AA1 P07900 2/20 0.60
HSP90AB1 P08238 2/20 0.60
POLB P06746 2/20 0.58
MAPT P10636 2/20 0.58
KDM4E B2RXH2 1/20 0.58
NR1I2 O75469 1/20 0.58
TP53 P04637 1/20 0.58
CYP3A4 P08684 1/20 0.58
F13A1 P00488 1/20 0.56
TGM2 P21980 1/20 0.56
MKNK2 Q9HBH9 2/20 0.52
MKNK1 Q9BUB5 1/20 0.51
KLK7 P49862 1/20 0.50
KLK5 Q9Y337 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29885475 0.94 MAOA (0.57) MAOAMAOBLMNASMN1; SMN2ESR2
SCHEMBL2314134 0.84 OPRD1 (0.62) MAOAMAOBSMN1; SMN2POLBMAPT
SCHEMBL3366271 0.84 OPRD1 (0.62) MAOAMAOBSMN1; SMN2POLBMAPT
SCHEMBL29477243 0.83 LMNA (0.50) MAOAMAOBLMNASMN1; SMN2ESR2
SCHEMBL24210580 0.83 LMNA (0.79) MAOAMAOBLMNASMN1; SMN2ESR2
SCHEMBL10150353 0.80 MKNK2 (0.59) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
SCHEMBL28721233 0.80 CYP19A1 (0.56) MAOAMAOBLMNASMN1; SMN2ESR2
SCHEMBL869065 0.79 LMNA (0.88) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
SCHEMBL29737259 0.79 LMNA (0.88) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1
SCHEMBL31217635 0.79 LMNA (0.88) LMNASMN1; SMN2ESR2ALDH1A1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368695-A1 Atranorin biosynthesis gene derived from lichens and uses thereof INDUSTRY ACADEMIC COOPERATION FOUNDATION OF SUNCHON NATIONAL UNIV (KR) 2025-12-04 US disclosed
EP-3599853-B1 HERBICIDAL COMPOSITIONS AND METHODS OF USE THEREOF UNIV CALIFORNIA (US) 2025-07-30 EP disclosed
US-20240043850-A1 COMPOSITIONS AND METHODS FOR TYPE III POLYKETIDE PRODUCTION IN OLEAGINOUS YEAST SPECIES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2024-02-08 US disclosed
US-11820987-B2 Compositions and methods for type III polyketide production in oleaginous yeast species BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-11-21 US disclosed
WO-2022260402-A1 ATRANORIN BIOSYNTHESIS GENE DERIVED FROM LICHEN AND USE THEREOF 순천대학교 산학협력단 2022-12-15 WO disclosed
CN-112915079-A Application of compound 6-hydroxy meleumycin in preparing anti-tumor medicine 江西科技师范大学 2021-06-08 CN disclosed
US-20200037609-A1 HERBICIDAL COMPOSITIONS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-02-06 US disclosed
EP-3599853-A1 HERBICIDAL COMPOSITIONS AND METHODS OF USE THEREOF The Regents of the University of California (US) 2020-02-05 EP disclosed
US-20190078098-A1 COMPOSITIONS AND METHODS FOR TYPE III POLYKETIDE PRODUCTION IN OLEAGINOUS YEAST SPECIES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-03-14 US disclosed
CN-109415681-A For producing the composition and method of type III polyketone in oleaginous yeast kind 德克萨斯大学系统董事会 2019-03-01 CN disclosed
WO-2012129450-A1 MICROBIAL PRODUCTION OF CHEMICAL PRODUCTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS OPX BIOTECHNOLOGIES, INC. (US) 2012-09-27 WO disclosed
US-8119385-B2 Nucleic acids and proteins and methods for making and using them BP CORPORATION NORTH AMERICA INC. (US) 2012-02-21 US disclosed
US-20110296543-A1 NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM THE UNIVERSITY OF CALIFORNIA (US) 2011-12-01 US disclosed
WO-2011094457-A1 MICROORGANISM PRODUCTION OF HIGH-VALVE CHEMICAL PRODUCTS, AND RELATED COMPOSITIONS, METHODS AND SYSTEMS OPX BIOTECHNOLOGIES, INC. (US) 2011-08-04 WO disclosed
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2010-01-14 US disclosed
US-20100011456-A1 Nucleic Acids and Proteins and Methods for Making and Using Them VERENIUM CORPORATION (US) 2010-01-14 US disclosed
US-20080161324-A1 Compositions and methods for treatment of viral diseases EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) 2008-07-03 US disclosed
WO-2008033466-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PRE. LTD. (SG) 2008-03-20 WO disclosed
EP-0906114-B1 ANTIPSORIATIC COMPOSITIONS COMPRISING AN ASPHODELUS EXTRACT, METHOD OF MAKING, AND METHOD OF USING MOADY SAID (US) 2002-06-26 EP disclosed
EP-1166791-A2 Antipsoriatic compositions comprising an asphodelus extract, method of making, and method of using Moady, Said (US) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES HTR1A, HTR3B, HTR3A MAOA 32/4885MAOB 26/4885LMNA 692/4885
US-20080161324-A1 Compositions and methods for treatment of viral diseases HAVCR2, EIF2AK2, RNASE1 MAOA 1703/4885MAOB 996/4885LMNA 624/4885
US-20200037609-A1 HERBICIDAL COMPOSITIONS AND METHODS OF USE THEREOF DDT, ASPH, AS3MT MAOA 775/4885MAOB 698/4885LMNA 3781/4885
US-20100011456-A1 Nucleic Acids and Proteins and Methods for Making and Using Them POLN, POLM, POLI MAOA 674/4885MAOB 1129/4885LMNA 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.